oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Metformin increases AMP-activated-protein-kinase activity in skeletal of subjects with type 2 diabetes
Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Karolinska Institute, Centre of Gastrointestinal Disease, Ersta Hospital, Stockholm, Sweden.
Department of Surgery, Huddinge University Hospital, Huddinge, Sweden.
Vise andre og tillknytning
2002 (engelsk)Inngår i: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 51, nr 7, s. 2074-2081Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.

sted, utgiver, år, opplag, sider
Alexandra, VA, USA: American Diabetes Association Inc. , 2002. Vol. 51, nr 7, s. 2074-2081
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-64078DOI: 10.2337/diabetes.51.7.2074ISI: 000176616200011PubMedID: 12086935Scopus ID: 2-s2.0-0036299982OAI: oai:DiVA.org:oru-64078DiVA, id: diva2:1173362
Merknad

Funding Agency:

NIAMS NIH HHS

Tilgjengelig fra: 2018-01-12 Laget: 2018-01-12 Sist oppdatert: 2018-01-16bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Ljungqvist, Olle

Søk i DiVA

Av forfatter/redaktør
Ljungqvist, Olle
Av organisasjonen
I samme tidsskrift
Diabetes

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 119 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf